Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07215351 · ClinicalTrials.gov registry record · NA
Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women
A NA study of Constipation and Bloating, sponsored by University of Memphis.
- Recruiting
- Registry status
- NA
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT07215351: Recruiting NA study of Constipation and Bloating, sponsored by University of Memphis.
NCT07215351 is a NA study of Constipation and Bloating that is actively recruiting participants, run by University of Memphis. The registered enrollment target is 30 participants, below the 205-participant average among 54 other Constipation trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07215351, a NA study of Constipation and Bloating, is actively recruiting participants, sponsored by University of Memphis.
- RECRUITING
- Registry status
- NA
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the present study is to investigate the impact of a natural dietary supplement, Inno Cleanse™, to reduce bloating in a population of otherwise healthy men and women, who claim to feel frequently bloated. Inno CleanseTM dietary supplement is manufactured in the United States under current Good Manufacturing Practices (cGMP) and is marketed by InnoSupps as a digestive health aid. It is sold in the United States on the company's website, Amazon, and in many large retail outlets. It remains a very popular product, with close to 1.4 million units sold since 2020, with a reported 66,000 units sold in the past three months. Despite the prevalence of dietary supplements identifying as digestive aids, detoxification, and cleanses, very little research has been done to determine their effectiveness. The product appears to be well-designed, with multiple ingredients included which have scientific evidence of effectiveness. That said, and despite the overall positive reviews, there is no known clinical research to support the product's effectiveness. Therefore, the aim of this study is to evaluate the efficacy of the Inno Cleanse product to reduce bloating and result in other positive outcomes (weight loss). This study will be run as a double-blind placebo-controlled trial, in which subjects will use the product or placebo for two weeks. It is hypothesized that treatment with the dietary supplement Inno Cleanse will result in reduced bloating, as evidenced by self-reported reductions in bloating and hunger, as well as moderate weight loss and a reduction in body circumference measures due to the reduced bloating. In addition, multiple anecdotal reports of improved skin health have been noted in those using the product. Additionally, routine blood and urine sample analysis will be performed as a secondary outcome, as a safety measure.
Primary Outcome
Alanine transaminase measured as part of metabolic panel in international units per liter
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Dietary supplement for digestive health
- DIETARY_SUPPLEMENT placebo capsule
Study Locations (1)
Tennessee
- Center for Nutraceutical and Dietary Supplement Research - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-10-07 |
| Est. Completion | 2026-01-01 |
| Phase | NA |
What NCT07215351 shows while recruiting
NCT07215351 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 205-participant average among 54 other Constipation trials with a reported enrollment target (85% lower).
The record links to 2 conditions, with Constipation appearing as the primary indexed condition, and to 2 interventions - of which Dietary supplement for digestive health is the first listed.
NCT07215351 reports a single indexed study location in Tennessee.
Frequently Asked Questions
What is clinical trial NCT07215351 about?
NCT07215351 is a clinical study titled "Impact of the Inno Cleanse Dietary Supplement on Gut Health and Associated Variables in Healthy Men and Women". The purpose of the present study is to investigate the impact of a natural dietary supplement, Inno Cleanse™, to reduce bloating in a population of otherwise healthy men and women, who claim to feel frequently bloated. Inno CleanseTM dietary supplement is manufactured in the United States under curr...
What is the current status of trial NCT07215351?
This trial is currently recruiting. It is a NA study. The enrollment target is 30 participants. The study started on 2025-10-07. Estimated completion is 2026-01-01.
What conditions does trial NCT07215351 study?
This clinical trial studies the following conditions: Constipation, Bloating.
What interventions are being tested in trial NCT07215351?
The interventions under investigation include: Dietary supplement for digestive health (DIETARY_SUPPLEMENT), placebo capsule (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT07215351?
This trial is sponsored by University of Memphis, which has 35 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07215351 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Constipation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07215351's enrollment target sits among peer trials
30 40th of 54 higher than 13 of 54 other Constipation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Constipation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Optimization of Postoperative Bowel Habits
RECRUITING · NA
-
Management of Dyssynergic Defecation
RECRUITING · NA
-
Interrogating the Pathophysiological Mechanisms of Constipation in Patients With Systemic Sclerosis
RECRUITING · NA
-
Fecobionics in Biofeedback Therapy in Dyssynergia Patients
RECRUITING · NA
-
Understanding Mechanisms of Normal and Disordered Defecation
RECRUITING · NA
-
Impact of Weizmannia (Bacillus) Coagulans JBI-YZ6.3 on Gut Health and Fecal Microbiome Changes
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI